World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
45149
World Ranking
5766
National Ranking
3099

David P. Kelsen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David P. Kelsen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 485 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David P. Kelsen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David P. Kelsen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David P. Kelsen is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research portfolio is primarily centered around cancer, with a strong focus on pancreatic and hepatic oncology, as well as cancer genomics and diagnostics.

Their recent publications include:

  • Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation, 2020, Journal of Clinical Oncology
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial, 2020, The Lancet Oncology
  • Tumour extracellular vesicles and particles induce liver metabolic dysfunction, 2023, Nature
  • Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection, 2020, Clinical Cancer Research
  • Artificial Intelligence and Early Detection of Pancreatic Cancer, 2021, Pancreas

David P. Kelsen has frequently collaborated with a range of researchers, including:

  • Eileen M. O'Reilly
  • Kenneth H. Yu
  • Marinela Capanu
  • Wungki Park
  • Anna M. Varghese

Their work is often published in prominent venues such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • Nature Communications
  • Clinical Cancer Research
  • Cancer

Their main fields of study are concentrated in:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their research covers a number of subfields, including:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Surgery

The topics addressed in their publications focus heavily on:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer
  • Gastric Cancer Management and Outcomes
  • Extracellular vesicles in disease
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers

Best Publications

  • Comprehensive molecular characterization of gastric adenocarcinoma

    Adam J. Bass;Vesteinn Thorsson;Ilya Shmulevich;Sheila M. Reynolds

  • INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

    Bruce D. Minsky;Thomas F. Pajak;Robert J. Ginsberg;Thomas M. Pisansky

  • Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer

    David P. Kelsen;Robert Ginsberg;Thomas F. Pajak;Daniel G. Sheahan

  • Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

    Ki Young Chung;Jinru Shia;Nancy E. Kemeny;Manish Shah

  • Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

    Ayuko Hoshino;Ayuko Hoshino;Han Sang Kim;Han Sang Kim;Linda Bojmar;Linda Bojmar;Linda Bojmar;Kofi Ennu Gyan

  • Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and Vomiting

    Richard J. Gralla;Loretta M. Itri;Sharon E. Pisko;Anna E. Squillante

  • Long-term results of RTOG trial 8911 (USA intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer

    David P. Kelsen;Katryn A. Winter;Leonard L. Gunderson;Joanne Mortimer

  • Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

    Ephraim S. Casper;Mark R. Green;David P. Kelsen;Robert T. Heelan

  • Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor

  • Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

    Richard J. Gralla;Ephraim S. Casper;David P. Kelsen;David W. Braun

  • Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin

    M G Kris;R J Gralla;R A Clark;L B Tyson

  • Hypermethylated APC DNA in Plasma and Prognosis of Patients With Esophageal Adenocarcinoma

    Kazuyuki Kawakami;Jan Brabender;Reginald V. Lord;Susan Groshen

  • FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

    D Kelsen;O T Atiq;L Saltz;D Niedzwiecki

  • Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

    Y.Y. Janjigian;D. Werner;C. Pauligk;K. Steinmetz

  • Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy.

    Bruce D. Minsky;Alfred M. Cohen;Nancy Kemeny;Warren E. Enker

  • Small-Cell Carcinomas of the Gastrointestinal Tract: A Review

    Baruch Brenner;Laura H. Tang;David S. Klimstra;David P. Kelsen

  • Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

    Leonard Saltz;Bonnie Trochanowski;Marcia Buckley;Bernadette Heffernan

  • Molecular Classification of Gastric Cancer: A New Paradigm

    Manish A Shah;Raya Khanin;Laura H Tang;Yelena Y. Janjigian

  • Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus

    Jaffer A. Ajani;David H. Ilson;Karen Daugherty;Richard Pazdur

  • Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer

    Alison Grann;Bruce D. Minsky;Alfred M. Cohen;Leonard Saltz

Frequent Co-Authors

Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Manish A. Shah
Manish A. Shah Cornell University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Laura H. Tang
Laura H. Tang Memorial Sloan Kettering Cancer Center
Gary K. Schwartz
Gary K. Schwartz Memorial Sloan Kettering Cancer Center
Ghassan K. Abou-Alfa
Ghassan K. Abou-Alfa Memorial Sloan Kettering Cancer Center
Manjit S. Bains
Manjit S. Bains Memorial Sloan Kettering Cancer Center
Bruce D. Minsky
Bruce D. Minsky The University of Texas MD Anderson Cancer Center
Nancy E. Kemeny
Nancy E. Kemeny Memorial Sloan Kettering Cancer Center
Daniel G. Coit
Daniel G. Coit Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical degree in the USA opens the door to a wide range of related online degrees and accelerated career pathways. For those looking to advance quickly, the fastest dnp online program options can help students earn a Doctor of Nursing Practice degree in less time compared to traditional routes. These programs are ideal for working professionals aiming to step up into leadership or specialized practice roles.

If you prefer a less intensive route, consider the easiest dnp program online, which provides a flexible and manageable curriculum for nurses balancing work and study. For those seeking entry-level opportunities, the lpn fast track program allows a quicker path to begin a healthcare career as a Licensed Practical Nurse.

Mental health is another in-demand field, and the psych nurse practitioner programs offer accelerated ways to specialize in psychiatric mental health care. With a flexible online format, these programs support students seeking specialized credentials and a rewarding future in healthcare.

Best Scientists Citing David P. Kelsen

Trending Scientists

Recently Published Articles